Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. could be a weak company given it's low Piotroski F-score. The momentum for this stock is not very good. Larimar Therapeutics, Inc. is not a good value stock. Larimar Therapeutics, Inc. has good growth characteristics. Larimar Therapeutics, Inc. is not very popular among insiders. Larimar Therapeutics, Inc. is a mediocre stock to choose.
Log in to see more information.
LRMR Fundamental Data by TradingView

News

Larimar Therapeutics initiated with bullish view at JonesResearch, here's why
Larimar Therapeutics initiated with bullish view at JonesResearch, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Larimar Therapeutics (NASDAQ:LRMR) Coverage Initiated by Analysts at Robert W. Baird
Larimar Therapeutics (NASDAQ:LRMR) Coverage Initiated by Analysts at Robert W. Baird

Zolmax Equities research analysts at Robert W. Baird started coverage on shares of Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) in a research report issued on Wednesday, MarketBeat.com reports. The...\n more…

Larimar Therapeutics (NASDAQ:LRMR) Upgraded to Strong-Buy by Baird R W
Larimar Therapeutics (NASDAQ:LRMR) Upgraded to Strong-Buy by Baird R W

Zolmax Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) was upgraded by research analysts at Baird R W to a "strong-buy" rating in a report issued on Wednesday, Zacks.com reports.\nA number of other...\n more…

Larimar Therapeutics to Participate in Upcoming Investor Conferences
Larimar Therapeutics to Participate in Upcoming Investor Conferences

Globe Newswire BALA CYNWYD, Pa., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...\n more…

William Blair Research Analysts Decrease Earnings Estimates for Larimar Therapeutics, Inc. (NASDAQ:LRMR)
William Blair Research Analysts Decrease Earnings Estimates for Larimar Therapeutics, Inc. (NASDAQ:LRMR)

Ticker Report Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - William Blair lowered their Q3 2024 EPS estimates for shares of Larimar Therapeutics in a research note issued on Wednesday, August 7th...\n more…

Q3 2024 EPS Estimates for Larimar Therapeutics, Inc. (NASDAQ:LRMR) Lowered by Leerink Partnrs
Q3 2024 EPS Estimates for Larimar Therapeutics, Inc. (NASDAQ:LRMR) Lowered by Leerink Partnrs

Ticker Report Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Analysts at Leerink Partnrs dropped their Q3 2024 earnings per share estimates for Larimar Therapeutics in a report issued on Wednesday...\n more…